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This review is based on the JR Vane Medal Lecture presented at the BPS Winter Meeting in December 2014 by T. Kenakin. A
recording of the lecture is included as supporting information and can also be viewed online here: https://www.youtube.com/
watch?v=xrP81AQ8l-8. Pharmacological models used to describe drug agonism and antagonism have evolved over the past
20 years from a parsimonious model describing single active and inactive receptor states to models of multiconformational
receptor systems modified by ligand conformational selection. These latter models describe the observed, presently
underexploited, pharmacological mechanism of ligand-directed biased signalling. Biased signals can be quantified with
transduction coefficients (ΔΔLog(τ/KA) values), a scale grounded in the Black/Leff operational model; this enables the
optimization of biased profiles through medicinal chemistry. The past decades have also brought the availability of new
technologies to measure multiple functional effects mediated by seven transmembrane receptors. These have confirmed that
drugs can have many efficacies, which may be collaterally linked, that is there is no linear sequence of activities required. In
addition, new functional screening assays have introduced increasing numbers of allosteric ligands into drug discovery. These
molecules are permissive (they do not necessarily preclude endogenous signalling in vivo); therefore, they may allow better
fine tuning of pathological physiology. The permissive quality of allosteric ligands can also change the quality of endogenous
signalling efficacy (‘induced bias’) as well as the quantity of signal; in this regard, indices related to ΔΔLog(τ/KA) values
(namely ΔLog(αβ) values) can be used to quantify these effects for optimization in the drug discovery process. All of these
added scales of drug activity will, hopefully, allow better targeting of candidate molecules towards therapies.
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Introduction
Pharmacology is the chemical control of physiology and drug
therapy involves some rather simple chemical interactions
controlling a vast and complicated network of cells and bio-
chemical processes. A critical component of a pharmacologi-
cal system is a pharmacodynamic model to visualize and
quantify the molecular events that begin with the drug
binding to the target and culminate in a modification of
cellular function. Over the past 20 years, new knowledge and
new functional assays through advances in technology have
brought on a Renaissance in the pharmacological models
used in drug discovery. Central to these models is the defini-
tion of the receptor active state, thus it is useful to begin by
describing receptor-activation models.
The evolution of models of agonism
Historically, the byword in the development of pharmaco-
logical models to describe drug–receptor interactions has
been parsimony; why construct unduly complex models
until you have to? A key example of a parsimonious model
developed to describe a complex process involves the descrip-
tion of agonist efficacy. This is one of the most, if not the
most, unique concepts in pharmacology. Efficacy is the prop-
erty of a molecule that causes the biological target to change
its behaviour towards its host (cell) when the drug binds to it.
The most simple model to describe efficacy is to assume that
the biological target (the model for this discussion will be
seven transmembrane receptors – 7TM receptors) acts as an
on and off switch having an active state and an inactive state
and that agonists produce cellular activation by turning on
the switch. In thermodynamic terms, this would be a system
where the agonist enriches the prevalence of the single recep-




































The ligand A can control the enrichment or reduction of
Ractive, which is normally controlled by an allosteric constant
L, selectively binding to one of the receptor states. Thus, if α
> 1, then the ligand A has a preferential affinity for the active
state and stabilizes it. This, in turn will enrich the active state
(and in this case cause agonism). If α < 1, then the reverse
occurs and the ligand is an inverse agonist reversing consti-
tutively activated systems (i.e. those with a substantial
ambient level of active state receptor). This is shown by the
equation describing the change in Ractive produced by the
binding of a saturating concentration of ligand A:
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It can be seen from equation 2 that if α = 1, that is, if the
ligand has an equal affinity for both states of the receptor,
then ligand binding will not change the relative amounts of
the active and inactive species. However, if α ≠ 1, then ligand
binding will inevitably change the makeup of the system in
terms of the relative amounts of Ractive and Rinactive. This scheme
treats the receptor as a rheostat that is scalable only in terms
of the strength of the signal, not the type of signal, it can
impart.
This model of efficacy yielded one of the most important
tools in the pharmacology of drug discovery, namely the
agonist potency ratio. The fact that all agonists were thought
to enrich a single receptor active state allowed the assump-
tion that cells dealt with all agonist stimuli in a uniform way,
that is, there was a single stimulus-response function to
















Aripiprazole GLP-1 (7-36)NH2 Pergolide
Bromocriptine M-5MPEP Phenoxybenzamine (POB)




These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
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response. This assumption that the stimulus response func-
tion is monotonic (only one value of y for every x) means
that ratios of observed agonist effect also reflect ratios of
stimulus. This, in turn, allows agonist potency ratios found in
test systems to be predictive of the same in all, including
therapeutic, systems, that is the cell is simply a transducer of
the receptor-mediated stimulus.
When functional pharmacological studies were confined
to a limited array of systems (e.g. animal isolated tissues),
there was insufficient data to challenge the parsimonious
single receptor active state model. As exceptions to a single
receptor state were noted, more complex receptor models
were constructed, for example the three-state receptor
model (Scaramellini and Leff, 2002). The acceptance of a
single receptor model began to wane when recombinant
systems became available. In these, a much larger array of
receptor-effector combinations with varying stoichiometries
could be studied. As recombinant functional pharmacology
became commonplace, it became evident that 7TM recep-
tors are pleiotropic with respect to the number of cellular
interactants they can engage. An early theoretical treatment
of the possible ramifications of this shows that unless the
receptor species mediating the initial stimulus to these
pleiotropic interactants are identical for each agonist, differ-
ences in the resulting overall cellular response are predicted
(Kenakin and Morgan, 1989). Interestingly, prior to this
theoretical treatment, isolated papers describing experimen-
tal data that did not conform to the single receptor active
state hypothesis had already been published. For instance,
as stated by Roth and Chuang (1987): ‘. . . the possibility is
raised that selective agonists and antagonists might be
developed which have specific effects on a particular
receptor-linked system’.
In retrospect, it should not have been surprising that
pleiotropic interactants with receptor species would lead to
heterogeneity in signalling as 7TM receptors are allosteric
proteins. Therefore, it would be predicted from the allosteric
theory that the conformation of the receptor interacting with
ligands will be dependent on the nature and concentration of
the co-binding species. In the light of the reciprocal energy
changes involved in protein binding, it would also be pre-
dicted that different receptor conformations stabilized by
ligands will confer differing affinities and efficacies for the
functional activation of the co-reactants, for example cellular
coupling proteins mediating signalling. In other words, dif-
ferent receptor conformations would lead to different signal-
ling characteristics.
With increasing reports from recombinant systems, it
became evident that a uniform receptor active state confor-
mation was insufficient to describe agonist pharmacology. A
particularly clear cut example of where experimental data
specifically refuted the concept that a monotonic relation-
ship exists between receptor activation and cellular response
was reported for the PACAP receptors. The unique aspect of
this study was the fact that two response pathways linked to
the PACAP receptor (namely cAMP and IP3 production) could
be monitored separately (Spengler et al., 1993). In this
system, two agonists (PACAP1–27 and PACAP1–38) had opposite
relative potencies for the two pathways as they interacted
with a single receptor; such reversals are not possible to
explain with a single receptor state model (Kenakin, 1995).
These data clearly showed how different agonists possess dif-
ferent qualities of efficacy as well as different quantities of
efficacy.
The stabilization of different receptor active states is a
workable model for reversals in agonist potency such as that
shown with the PACAP receptor (Kenakin, 1995). In fact, 17
years after this idea was proposed on theoretical grounds,
direct evidence for ligand-specific receptor conformations has
been described in studies using [19F]-NMR (Liu et al., 2012).
Molecular mechanisms describing how such effects can occur
are found in molecular dynamic descriptions of protein func-
tion. Pioneering work by Onaran and Costa (Onaran and
Costa, 1997; Onaran et al., 2002) introduced molecular
dynamics into pharmacology with descriptions of how
ligands can interact with a multitude of conformations and
differentially stabilize them through selective binding. This
model of agonism does not rely on the pre-identification of
receptor states, but rather describes the control of undefined
collections of conformations (referred to as protein ensem-
bles) (Fraunfelder et al., 1988; 1991; Freire, 1998) by ligands
through probability functions. A visual description of the
dynamics of receptor function in this scheme is given as an
energy landscape. Thus, the receptor protein is seen to roll on
an energy landscape which describes many energy wells into
which the receptor may enter and remain for a length of time
commensurate with the molecular forces governing the ter-
tiary structure of the receptor. At any one instant, if this
system were to be frozen in time it would be seen that a
collection of protein conformations (the ensemble) would be
what ligands encounter. The process of conformational selec-
tion (Burgen, 1981) (preferred binding to conformations for
which the ligand has a high affinity) converts the ensemble
into a ligand-bound collection of states that are unique to the
ligand and receptor through the application of Le Chatelier’s
principle (‘. . . if a dynamic equilibrium is disturbed by
changing the conditions, the position of the equilibrium
moves to counteract the change’).
An advantage of this dynamic molecular approach is the
lack of a required definition of receptor states. The observa-
tion of bias signalling clearly negates a single active state
receptor model raising the question, how many active states
are there? This question is compounded by the context in
which it can be asked, namely, what receptor activities will be
mediated by these active states? With the advent of specific
assays to measure distinct receptor behaviours has come a
multiple array of possible efficacies for drugs, a condition
described by Galandrin and Bouvier (2006) as ‘pluridimen-
sional efficacy’. Therefore, not only is there a possibility of
multiple receptor active states, there also is a possibility of
multiple ligand-driven receptor efficacies. Models that require
a predefinition of all these possibilities become exceedingly
cumbersome with a need for too many unverifiable param-
eters to be useful. This paved the way for probabilistic models
whereby ligands contributed energy to the stabilization of
certain conformations, at the expense of others, with no
predefinition of what function those receptor states con-
trolled (Onaran and Costa, 1997; Kenakin, 2002; Onaran
et al., 2002). This also removed the constraint of linearity to
the existing models of efficacy. Specifically, a single receptor
active state necessitates a condition whereby only the
strength of the signal controls what constellation of signal-
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ling pathways are recruited by any given ligand. With a
probabilistic model of multiple states, a different condition to
ligand efficacy applies whereby ligands can instil collateral
efficacy to systems, that is, ligands can have unique arrays of
efficacies depending on their chemical structure. Within the
context of this model, the particular array of efficacies any
given ligand can have depends upon the relative affinities the
ligand has for the various receptor conformations mediating
those efficacies. As shown in Figure 1, various ensembles of
conformations are associated with receptor functions and, as
ligands bind to the receptor ensemble and stabilize various
conformations, ligand functions emerge as a result of which
conformations are selectively stabilized. Figure 1 shows
a hypothetical ligand in panel A that produces Gs and
β-arrestin activation but no receptor internalization. A hypo-
thetical ligand B (panel B) activates Gs, Gi and β-arrestin and
also internalizes the receptors. The heights of the various
histograms produced by ligand stabilization represent the
relative strength of signal for each efficacy. It can be seen that
different ligands can have quite different and unrelated sets
of efficacies within this model depending on the relative
affinity the ligands have for the different conformations
within the ensemble (Onaran and Costa, 1997; Kenakin,
2002; Onaran et al., 2002). One of the most striking dissocia-
tions of efficacy from the conventional linear model are
ligands that produce no visible receptor activation (i.e. are
receptor antagonists) but also actively internalize receptors
(Roettger et al., 1997; Gray and Roth, 2001).
One important prediction of an ensemble model of
receptor conformation involves the interaction of such
ensembles with ligands. Assuming that a given ligand will
not have identical affinities for all the conformations in an
ensemble, it would be predicted that ligand interaction with
an ensemble will inevitably change the makeup of the
ensemble, that is, the relative proportions of the various
conformations will change. The corollary to this idea would
be that ligand binding is an active, not a passive, process
and the modification of ensembles most likely to occur
would lead to an observed ‘efficacy’ for that ligand if the
stabilized conformations are related to cellular function.
This would modify the historical dogma that all drugs have
affinity but only agonists have efficacy to a more general
idea that potentially all drugs have affinity and efficacy. The
key to discovering such new efficacies is to have the phar-
macological assay to detect effect. The observation of mul-
tiple drug efficacies (Galandrin and Bouvier, 2006) also leads
to the notion that the constellation of efficacies possessed
by any one ligand constitutes an important fingerprint of
activity that may control a therapeutic phenotype of value.
Expressions of such efficacies on multiple ordinate axes can
yield unique representations for the overall quality of drug
effect; this has been referred to as a ‘web of efficacy’ when
expressed in two-dimensional space (Evans et al., 2011;
Zhou et al., 2013). A striking phenomenon seen with these
representations is the fact that all drugs tested in the studies
demonstrate a unique web reflecting special collections of
efficacies, probably stemming from the stabilization of
unique collections of receptor active conformations within
the ensemble.
The concept of collateral efficacy allows for different com-
binations of efficacy for therapeutic advantage, that is the
identity of the active state receptor conformations stabilized
by any one ligand defines its pharmacological properties. By
implication, judicious application of pharmacological assays
and medicinal chemistry could control which conformations
are chosen from an ensemble and thus what pharmacological
properties a ligand would have (Kenakin, 2002). Therapeuti-
cally, this alters the drug discovery screening landscape from
one of ‘take what you get’ to a preferable one utilizing dis-
tinct, specific pharmacological assays of ‘get what you
choose’. The specific targets of this approach are ‘biased
ligands’ which could be tailored to have specific arrays of
efficacy. The positive side of this idea is the potential to
improve drugs by emphazing beneficial efficacies and/or
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Receptor conformational ensembles displayed as Boltzman distribu-
tions. Shown are selected ensembles with pharmacological functions
(except for ‘inactive’ state which has no cellular outcome). Superim-
posed on these distributions are the stabilized conformations,
through conformational selection, made by two hypothetical ago-
nists A and B. The coincidence of the ligand-stabilized conformations
with the functional ensembles confers the observed functional effi-
cacy to the ligand. Ligand A produces activation of Gs protein and
β-arrestin; ligand B activates Gs and Gi protein, β-arrestin and also
causes receptor internalization.
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tive side of this approach is the elimination of monotonic
stimulus-response coupling and subsequent cell-dependence
of efficacy; this weakens the predicting power of tools such as
the agonist potency ratio (vide infra).
Biased agonists
A biased agonist stabilizes a particular array of active receptor
conformations to preferentially activate some cell signalling
pathways over others (Kenakin, 1995). A common area of
such selection is ligands that produce heterogeneous activa-
tion of G protein versus β-arrestin signalling pathways in
cells. For example, selective activation of β-arrestin (over G
protein) by ligands has been postulated to be beneficial for
congestive heart failure (Violin and Lefkowitz, 2007; Violin
et al., 2010; Boerrigter et al., 2011), osteoporosis (Ferrari et al.,
2005; Gesty-Palmer et al., 2006; 2009) and GPR109-mediated
reduction of triglycerides and elevation of high-density lipo-
protein (Walters et al., 2009). Similarly, an opposite bias of
de-emphasis of β-arrestin signalling over G protein signalling
has been proposed to be beneficial for opioid-induced anal-
gesia without respiratory depression (Varga et al., 2004;
Raehal et al., 2005; Groer et al., 2007; DeWire et al., 2013). It
should not be blithely assumed that limiting ligand-based
signalling will unanimously improve drug profiles. All physi-
ological system signalling is naturally biased (for reasons of
physiological advantage); therefore, the introduction of a
synthetic bias will perturb a natural condition and this may
have adverse outcomes as well. However, assuming a given
bias has been identified as being therapeutically advanta-
geous; theoretically, this drug property can be enhanced
through medicinal chemistry. An important tool in this
regard is a quantitative scale for the determination of signal-
ling bias in ligands; a viable candidate for such a scale is the
‘transduction coefficient’, defined in terms of the Black/Leff
operational model as the parameter ΔΔLog(τ/KA) where τ is
the efficacy and KA is a measure of affinity of the ligand for
production of defined signalling responses (Kenakin et al.,
2012). This number quantifies the relative power of activa-
tion of two signalling pathways through activation of the
same receptor by a ligand. All that is required for the quan-
tification of bias with this tool are concentration-response
curves to the ligand and a reference agonist for both signal-
ling systems. Transduction coefficients can be obtained by
directly fitting the Black/Leff operational model to the curves
or, if the Hill coefficients of the curves are not significantly
different from unity, utilization of ‘Relative Activity’ values
(Ehlert, 2005; Figueroa et al., 2009; Tran et al., 2009) in the
form of ΔΔLog(RA).
It is relatively simple to calculate transduction coefficients
but it is important to interpret these numbers within their
limits. Figure 2 shows a range of dopamine agonists that
show biased activation of pERK signalling over adenylate
cyclase activation. Thus, as shown in Figure 2, FAUC321 is
10ΔΔLog(τ/KA) = 10−1.2 = 0.06 times less likely to activate adenylate
cyclase versus pERK when compared with the reference
agonist quinpirole (Tschammer et al., 2011). It is essential to
include a reference agonist as this allows any assay sensitivity
effects to be eliminated; it is not important which agonist is
used as the reference as the magnitude of relative biased





    
    
    
    
    
    
    






    
    
    
    
    







    
    
    






    



















































































Calculated in vitro bias of dopamine agonists on dopamine D2L receptors. ΔLog(τ/KA) values for each agonists in each pathway are calculated with
quinpirole as the reference agonist. Bias is then calculated as ΔΔLog(τ/KA) values. Graph on the right shows ΔΔLog(τ/KA) with 95% confidence
limits. Where those limits cross zero, there is no bias. Values outside of zero indicate statistically significant bias (P < 0.05). Thus, the bias for
FAUC321 is 10ΔΔLog(τ/KA) = 15.84. Redrawn from Tschammer et al. (2011).
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An important requirement for such an analysis is to assess
any difference statistically. The bars on the ordinate values in
Figure 2 depicting ΔΔLog(τ/KA) values are 95% confidence
limits; therefore, any value that does not include zero for this
index shows a P < 0.05 statistically significant bias. In this
example, the statistical limits of this measurement indicate
that the value for FAUC321 lies well outside of the 95%
confidence limits of the values for quinpirole thereby indi-
cating that FAUC321 produces 15.84 times more pERK signal
for a given cAMP signal than does quinpirole.
It is worth considering applications of the ΔΔLog(τ/KA)
scale beyond signalling bias. Specifically, Log(τ/KA) values
are basically a means of quantifying agonism with a single
number; this has important implications in other quantita-
tive areas of pharmacology. For instance, selective receptor
agonism is presently quantified through measurement of full
agonist potency ratios. This scale ceases to be useful in tissues
of low sensitivity when one or both of the agonists being
compared show partial agonism. Agonist potency ratios fail
to be uniform once partial agonism is observed, as seen from
the expression for the agonist potency ratios for agonists
denoted 1 and 2 defined by the Black/Leff operational model
















From equation 3, if τ > > 1, then potency ratio = (KA1/τ1)/(KA2/
τ2); this ratio will not change with changes in receptor
density. However, as τ approaches values lower than unity
(partial agonism), the ratio will deviate from the linear rela-
tionship and be dependent upon receptor density [RT] (since
τ = [RT]/KE where KE is the apparent Michaelis-Menten con-
stant of the cell as a virtual enzyme). This is not the case for
Log(τ/KA) values (and/or Log(RA) values for systems where n =
1) (Kenakin et al., 2012).
Another area of pharmacology where ΔΔLog(τ/KA) values
can be applied is in the assessment of receptor mutation.
With the discovery of constitutive 7TM receptor activity
(Costa and Herz, 1989; Samama et al., 1993) has come the
realization that receptors have efficacy. This is shown by the
fact that constitutively active receptor states activate signal-
ling proteins in the absence of agonists. While wild-type
receptors will have a natural bias coupling towards signalling
proteins, mutation of the receptor will most likely create a
different receptor conformation and this, in turn, may
change the bias of the mutated receptor towards signalling
effectors. In these instances, a natural agonist can be com-
pared with itself in the wild type versus mutant receptor
utilizing a synthetic agonist as a reference (to account
differences in receptor expression, transduction, etc., see
Tschammer et al., 2011; Belmer et al., 2014). Table 1 shows
data on the effects of mutating the dopamine D2L receptor.
Specifically, when agonism by dopamine is compared with
the reference quinpirole, it can be seen that the D2LH3936.55 A
mutation produces nearly insignificant effects on the ability
of dopamine to activate adenylate cyclase (10ΔΔLog(τ/KA) = 1.1),
whereas it induces a selective and significant reduction in the
ability of dopamine to activate the pERK pathway (10ΔΔLog(τ/KA)
= 0.076, a 13.18-fold diminution) (Tschammer et al., 2011).
Finally, transduction coefficients can be used to identify
unique host cell effects – these will be discussed further on
in this paper after consideration of the allosteric nature of
7TM receptors (vide infra). In general, the interpretation
of bias through this index is based on the allosteric nature
of 7TM receptors; thus, it is useful to discuss the allostery in
7TM receptors as a preface to further discussion of signal-
ling bias.
The allosteric nature of 7TM receptors
7TM receptors are nature’s prototypical allosteric protein,
that is they exist to change shape in accordance with the
binding of two co-binding bodies, usually extracellular
ligands (i.e. hormones, neurotransmitters) and cytosolic sig-
nalling proteins (i.e. G protein, β-arrestin) (Kenakin and
Miller, 2010; Kenakin, 2012). The affinity and efficacy
(defined as the change in behaviour of the receptor protein
towards its cellular host) of these bodies is inevitably depend-
ent on the nature and concentration of the co-binding body.
For example, as shown by X-ray crystallographic analysis, the
Table 1
Effect of point mutation of dopamine D2L receptors on responses to dopamine
Wild type
ΔΔLog(τ/KA)
D2L H3936.55 A mutant
Log(τ/KA) Δlog(τ/KA) Δlog(τ/KA) Log(t/KA)
cAMP
Quinpirole 8.680 0.040 6.690 Quinpirole
Dopamine 8.700 −0.020 −0.060 6.750 Dopamine
pERK
Quinpirole 8.410 −1.120 7.360 Quinpirole
Dopamine 8.620 −0.210 0.910 6.450 Dopamine
Data from Tschammer et al. (2011).
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conformation of the β2-adrenoceptor varies with the nature
of the co-binding body used to form the crystal (Rasmussen
et al., 2011a,b). The effects of various co-binding bodies on
the binding of (and subsequent effect of) a given ligand can
be quantified through parameters defining changes in the
affinity (through a cooperativity term α) and efficacy
(through a scaling term β) and these effects will be host
cell-independent. This is the case because they rely only on
the nature of the species comprising the ternary complex of
modulator/conduit/guest (i.e. ligand, receptors, signalling
protein). The quantitative model used to calculate these
parameters is an amalgam of the Stockton-Ehlert allosteric
receptor binding model (Stockton et al., 1983; Ehlert, 1988)
and the Black/Leff operational model for receptor function
(Black and Leff, 1983; see Figure 3). Thus, agonist [A] response
is given by (Ehlert, 2005; Kenakin, 2005; Price et al., 2005):
Response
A K B E
A K B
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(4)
where [B] is the modulator, KA and KB refer to the equilib-
rium dissociation constants of the agonist and modulator
complexes, respectively, α is the effect of the modulator on
the affinity of A, β is the effect of the modulator on the
efficacy of A, Em is the maximal response capability of the
system and n is the Hill coefficient of the concentration-
response curve. Through changes in α and β, the responses
to endogenous agonists can be blocked (α < 1 and/or β < 1)
or potentiated (α > 1 and/or β > 1) to yield basic phenotypic
changes in agonism (Ehlert, 2005; Kenakin, 2005; Price
et al., 2005). Modulators that increase the agonist response
are called positive allosteric modulators (PAMs) and those
that inhibit the response are negative positive modulators
(NAMs).
It is interesting to note that 7TM receptor agonism can be
thought of as a positive allosteric modulation of a receptor-
signalling protein interaction, that is, agonists are PAMs for
receptor–signalling protein interactions. This can be mod-
elled with the extended ternary complex model of 7TM
receptors (Samama et al., 1993). The spontaneous [Ra] active
state of the receptor will have an intrinsic affinity (KA) for the
signalling protein and an efficacy (τ) for the signalling
pathway (see Figure 4A). The agonist functions as a PAM for
the receptor–G protein interaction to give the receptor a new
affinity αKA and a new efficacy βτ. The modulator curves are
shown in Figure 4B where concentration-response curves for
the signalling protein (G protein) interacting with the recep-
tor are shown in the absence and presence of a range of
concentrations of a PAM. Any given combination of receptor
and G protein stoichiometric ratio (as would be defined in a
given tissue type) would yield a curve for the PAM that would
be manifest as direct agonism (the PAM is seen as a direct
agonist; see Figure 4B).
Thinking of 7TM receptor agonism as allosteric facilitation
of signalling protein function links a well-known feature of
allosterism to biased signalling, namely the concept of probe-
dependence. Specifically, allostery results in a change in the
conformation of the receptor and there is no reason to assume
that such a change in shape of the receptor will result in
identical changes in the interactions of probes of receptor
function at different loci on the protein. In fact, the evidence
to date suggests that the effects of a given allosteric modula-
tion on one probe may be quite different from the effects on
another probe in another region of the receptor; this is what is
referred to as probe-dependence. Considering two loci on the
cytosolic side of a receptor such as the binding site for a G
protein in one region and β-arrestin in another, probe-
dependence dictates that a given agonist-mediated change in







































The model of functional allosterism for receptors (Ehlert, 2005; Kenakin, 2005; Price et al., 2005). The receptor R binds a probe A (agonist) and
allosteric modulator B according to the Stockton-Ehlert allosteric binding model (Stockton et al., 1983; Ehlert, 1988). The ligand-bound species
produce response according to the Black/Leff operational model (Black and Leff, 1983). The parameters quantifying the effect of the modulator
are τ for possible direct agonism by the modulator, α for the effect of modulator on the affinity of the receptor for A and β for the effect of the
modulator on the efficacy of A.
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tions of the receptor with the G protein and β-arrestin. Thus,
different agonists may be biased (when compared with
another reference agonist). Under these circumstances, signal-
ling bias is no more than common receptor allosteric probe-
dependence.
Biased effects are also relevant to allosteric modulators
even when they do not produce direct stimulation of recep-
tors. This is due to the permissive nature of allosteric modu-
lators. Because these bind to sites on the receptor different
from the binding sites of endogenous agonists, they do not
automatically preclude the effects of endogenous signalling
(as do orthosteric ligands); the endogenous agonist may still
bind to the receptor and produce effect. Thus, the endog-
enous signalling system may still, in some way, function even
in the presence of binding of the allosteric ligand. If the
endogenous agonist produces pleiotropic signalling (activates
more than one signalling system in the cell to produce a
mixture of cytosolic effects), then allosteric ligands may
impart a change in the quality of the efficacy resulting from
endogenous signalling by changing the relative emphasis of
the pleiotropic signalling, that is, they may bias natural sig-
nalling. There are known cases of where this occurs for both
NAMs and PAMs. For example, while the natural NK2 receptor
agonist neurokinin A normally activates Gs and Gq, the NAM
LP1805 changes this pattern to one of enhanced Gq activa-
tion and blockade of Gs activation (Maillet et al., 2007). Simi-
larly, the NAM n-atosyltryptophan causes the CRF2 (CRH2)
receptor natural agonist PGD2 to change its profile from dual
activation of Gi and β-arrestin to sole activation of Gi protein
(with no concomitant β-arrestin interaction) (Mathiesen
et al., 2005). PAMs also change the nature of the signal
produced by endogenous agonism. The natural agonist of the
GLP-1 receptor, GLP-1(7-36)NH2 produces elevated cAMP,
calcium and pERK effects. The PAM NOVO2 causes potentia-
tion of the cAMP effects but has little effect on calcium and
pERK signalling of the endogenous agonist (Koole et al.,
2010). An extensive characterization of the calcimimetic PAM
bias has been done for the calcium-sensing receptor (see
Table 2) indicating bias for pERK1/2 activation, plasma mem-
brane ruffling and IP1 accumulation (Davey et al., 2012; Cook
et al., 2015).
As NAMs and PAMs can change not only the quantity of
the endogenous signal but also the quality of that signal,
additional parameters are required to characterize the phar-
macological activity of these molecules, that is the bias pro-
duced by allosteric ligands should be quantified in the same
manner as direct signalling bias of agonists. A scale analogous
to the ΔΔLog(τ/KA) scale can be derived from the functional
allosteric model (see Appendix for derivation) to yield an
index to do this, namely ΔLog(αβ). This parameter is the
difference between the product of the change in affinity and
efficacy of the endogenous agonist for any two signalling
pathways. For instance, the calcium receptor sensing PAM,
cinacalcet, potentiates calcium-induced intracellular calcium
release with an αβ value of 3.0 (Davey et al., 2012). However,
the αβ potentiation for calcium-induced pERK1/2 effects
is 1.9; this yields a small biased PAM effect towards intracel-
lular calcium release of 10Δlog(αβ) = 100.2 = 1.58 over pERK1/2
responses; a listing of various ΔLog(αβ) values is given in
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Direct agonism as a positive modulation of the interaction between receptors and G proteins. Top panel shows the extended ternary complex
model of receptors in inactive (Ri) and active (Ra) states interacting with G proteins (G) and ligands (A) (Samama et al., 1993). Constitutive
receptor activity is mediated by the spontaneous interaction of Ra with G according to Kg. This constitutive activity (black curve) is potentiated by
various concentrations of A to increase response through formation of the ARaG species. Observation of response for any specified concentration
of G protein illustrates the increased response to A, that is agonism in a system with defined concentrations of R and G.
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calcium oscillations with an αβ value of 0.01 and inositol
phosphate accumulation with an αβ value of 0.37 (Bradley
et al., 2011) to yield a bias of antagonism towards calcium
oscillations of 10Δlog(αβ) = 101.57 = 37-fold. Thus, 5MPEP has 37
times the blocking activity for calcium oscillations over ino-
sitol accumulation. In general, it may be that with permissive
allosteric molecules, quantitative data on induced bias
becomes as characteristic and useful as potency data in pre-
dicting therapeutic value.
Translation of biased effects in vivo
Using parameters from the operational model [ΔΔLog(τ/KA)]
and the functional allosteric model [Log(αβ)], direct and
induced biased effects can now be readily quantified.
However, the true value of biased ligands lies in how they
behave therapeutically in vivo and the assessment of this
value requires information beyond these indices. Specifically,
bias is a ratio of efficacy and affinity and the dominance of
which of these drug properties is important to how a biased
ligand behaves in tissues of varying receptor density. The
precedent for this effect has been set for agonism. Specifically,








Equation 5 shows that a high agonist potency can be
achieved by high affinity (low value of KA, this will be termed
affinity-dominant potency) and/or high efficacy (termed
efficacy-dominant potency) (Kenakin, 1984). The effects of
diminishing receptor density are different for each type of
agonist, as shown by an example comparing an affinity-
dominant agonist (oxymetazoline) and efficacy-dominant
agonist (carbachol) (see Figure 5). Agonism to an efficacy-
dominant agonist is much more robust with respect to reduc-
tions in receptor density than agonism for an affinity-
dominant agonist (Kenakin, 1997). As receptors are removed
by chemical alkylation, it can be seen that the response
to oxymetazoline is selectively depressed as compared with
the response to carbachol (see Figure 5). Thus, in a high-
sensitivity/high-receptor density tissue, oxymetazoline is
more potent than carbachol, but this condition is reversed in
a low-sensitivity/low-receptor density tissue and oxymetazo-
line becomes an antagonist.
This effect of affinity versus efficacy dominance is appli-
cable to biased agonism as well, that is, the bias towards a
given signalling pathway for a given agonist will be con-
trolled either by affinity or efficacy and this will, in turn,
determine the robustness of the bias in tissues of varying
receptor density. Figure 6 shows the effect of two biased ago-
nists with identical values of bias (bias = five times for
pathway 2); the bias of one agonist is based on affinity-
dominant while the other is efficacy-dominant. It can be seen
that the bias of the efficacy-dominant agonist is retained
throughout all levels of tissue sensitivity, whereas the bias of
the affinity-dominant agonist actually reverses in low-
sensitivity tissues. The fact that bias depends on both efficacy
and affinity also raises the possibility that bias can be
achieved with orthosteric antagonists as well (Kenakin, 2014)
to gauge the full spectrum of biased effects for any set of
agonists.
Biased ligands may be useful for one of two reasons: the
emphasis of a signalling pathway thought to be beneficial
(biased agonism) or the de-emphasis of a signalling pathway
that is thought to be detrimental (biased antagonism). It is
important to note that while bias describes relative agonism
when it is observed in any given system, the magnitude of
efficacy is still the determining factor of whether or not
agonism will be observed. Given this, biased ligands should
Table 2













Cinacalcet −0.19 0.65 −0.07 0.85 0.02 1.05
NPS-R568 −0.16 0.69 −0.24 0.58 0.05 1.12
Calindol 0.18 1.51 −0.06 0.87
S,R-calcimimetic B 0.1 1.26 0.49 3.09
R,R-calcimimetic B 0.2 1.58 0.23 1.70
Nor-calcimimetic B 0.02 1.05 0.15 1.41
AC-265347 0.34 2.19 −0.03 0.93
NAM
NPS-2143 0.29 1.95 0.01 1.02
Data from Davey et al. (2012) and Cook et al. (2015).
aΔlog(αβ) = Log(αβ)function − Log(αβ)Ca mobilization.
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be displayed on a graph with Cartesian coordinates of
Log(bias) as the abscissae and Log(relative maximal response)
as the ordinate (Kenakin, 2014) to display the full spectrum of
biased effects for any set of agonists (see Figure 7).
Another factor that is important in the translation of
biased effects in vivo is possible cell-based selectivity. It should
be noted that ΔΔLog(τ/KA) values quantify bias only within
the allosteric vector, that is, the ternary complex unit of
ligand, receptor and signalling protein (Kenakin and Miller,
2010). Within this context, α and β control ultimate signal-
ling effects and these parameters will be independent of the
cellular host and under these circumstances, the bias of the
Oxotremorine
Log [agonist]














































Muscarinic agonist responses in guinea pig ileum to oxotremorine and carbachol. Panel furthest to the left shows the control concentration-
response curves; oxotremorine is a threefold more potent full agonist than carbachol. Controlled chemical alkylation of receptors with
phenoxybenzamine (POB) produces a disparate depression of responses to the low efficacy agonist oxotremorine and resistance to loss of
receptors by carbachol. Redrawn from Kenakin (1997).
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Effects of reduction in receptor density in various systems on two types of biased agonist. In the top row, the bias, fivefold for pathway 1 (blue
line) is due primarily to a selective efficacy for pathway 1; pathway 1 τ = 10, KA = 2 μM; pathway 2 τ = 4, KA = 4 μM. Receptor concentrations from
left to right panels are [RT] = 10, 1, 0.1; note that the bias towards pathway 1 is maintained throughout all receptor levels. Lower row of panels
shows the effect of an agonist with the same bias (fivefold for pathway 1) but resulting from a selective affinity; pathway 1 τ = 3, KA = 2 μM;
pathway 2 τ = 30, KA = 100 μM. Receptor concentrations from left to right panels are [RT] = 10, 0.3, 0.01. Note how the bias at the lowest receptor
level reverses from pathway 1 > pathway 2 to pathway 2 > pathway 1.
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ternary complex will be a robust system-independent index.
If the signal emerging from the agonist-activated receptor is
uniform, then the cell simply provides amplification and cell
type will not affect agonist potency ratios (a monotonic
stimulus–response relationship). In contrast, if the signal
coming from the activated receptor is a biased mixture of
stimuli (i.e. activation of more than one G protein and/or
β-arrestin), then the type of cell could have an effect on the
overall response to the agonist as different pathways may
be heterogeneously important in different cell types (see
Figure 8; Kenakin and Christopoulos, 2013). Under these cir-
cumstances, the stimulus–response relationships for different
agonists may be different and this can lead to variations in
agonist potency ratios beyond that dictated by the allosteric
vector. There are numerous examples of this effect where
differences in cells and/or differences in the level at which a
response is measured cause variations in agonist potency
ratios. For example, the human calcitonin (CT) receptor
transfected into CHO cells yields relative potency ratios
(expressed as ratios of EC50 values) for porcine calcitonin = 1,
human calcitonin = 86.5 and human CGRP = 177; these same
agonists produce strikingly different potency ratios when
the same receptor is transfected into COS cells (porcine cal-
citonin = 1, human calcitonin = 2.7, human CGRP = 6)
(Christmanson et al., 1994). Similarly, the human calcitonin
receptor transfected into HEK cells yields an order of potency
for agonists of Eel Cal. > Porc. Cal. (Eel Cal. EC50/Porc. Cal.
EC50 = 0.25). Transfection of excess Gs protein into the same
cell actually reverses this potency ratio to Porc. Cal > Eel (Eel
Cal. EC50/Porc. Cal. EC50 = 8) (Watson et al., 2000). The level
of response measurement can also cause these effects. For
example, the relative order of potency for dopamine receptor
agonists in cells producing an elevation of cAMP (as ratios of
EC50 values) is 1:10:100 for pergolide, dopamine and bro-
mocriptine; these values would reflect numbers controlled by
the allosteric vector, that is activation of Gs protein by the
activated receptor. When label-free CellKey response (electri-
cal impedance) to these same agonists is measured in the



















































Grid for hypothetical-biased agonists for two pathways drawn as blue and red lines in the concentration-response curves. Ordinates represent
logarithms of the relative maximal responses to the agonists for each pathway as a ratio maximum for pathway 2/maximum for pathway 1.
Abscissae are logarithms of the bias of the agonists for pathway 2 over pathway 1. Four quadrants are defined. In the upper top quadrant,
compounds have a higher efficacy for pathway 2 but are biased towards pathway 1. In the lower right quadrant, compounds have a higher efficacy
for pathway 1 and also are biased towards pathway 1. The top left quadrant shows agonists that have a higher efficacy for pathway 2 over pathway
1 and are biased towards pathway 2 as well. The lower left quadrant shows agonists that have a higher efficacy for pathway 1 but are biased
towards pathway 2. The abscissal axis (ΔΔLog(τ/KA) indicates the relative concentrations where dose-response curves will appear (when the tissue
is sensitive enough to show agonism) when they do appear. The ordinal axis shows the relative ability of the agonists to produce the different
pathway responses. Effect on pathway 1, blue curve; effect on pathway 2, red curve.
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same cells (a response beyond the allosteric vector where the
cell can modify stimulus), the relative potencies change to 1:
2.6: 6.8 (Peters et al., 2007). This type of cellular modification
of measured bias in vitro may take place in vivo as the ligands
encounter different cell types containing the target receptors.
It is clear that bias measurements based on allosteric vectors,
although useful for identifying bias ligands, cannot always be
relied upon to predict whole cell response.
A positive aspect of this cell-type variability is the poten-
tial to detect biased ligands and also to identify unique thera-
peutic cell-type selectivity. Variation in agonist potency ratios
with varying cell types would be predicted only for biased
ligands. This being the case, if ligands are tested in whole
cell-based assays (such as label free assays) where the target
receptor is expressed in different cell lines, then those ligands
that show variation in potency ratios would be predicted to
be biased with respect to signalling.
The ΔΔLog(τ/KA) scale can also be useful for identification
of cell-specific agonism; one suitable experimental setting for
this approach is the comparison of agonist effect in label-free
systems. Figure 9 shows endogenous dopamine D1 receptor-
mediated electrical impedance responses in U-2 and SK-N-MC
cells. The bias plot identifies A77636 as having selective acti-
vation properties when the receptors are in U-2 versus
SK-N-MC cells (Peters and Scott, 2009); ΔΔLog(τ/KA) values
reveal an 11-fold difference. While in this case the direct
therapeutic relevance of these data may not be evident, other
scenarios for such effects could be, for example, tumour
versus normal cell lines. In general, if therapeutically relevant
cell types show unique reactivity to some ligands, these could
be advanced for disease-related therapies.
Another important aspect of biased ligands in vivo is the
fact that, as orthosteric molecules, they will interfere with
natural signalling due to endogenous agonists. There are
cases where it can be argued that this may be the most
important therapeutic property of the molecule as seen with
TRV120027. This biased angiotensin ligand produces no Gq
protein response but does initiate β-arrestin signals, which
can be beneficial to the failing myocardium. However, in
conditions of congestive heart failure, the occupancy of
angiotensin receptors to block angiotensin-induced vasocon-
striction may be the main therapeutic benefit of this mol-
ecule (Violin and Lefkowitz, 2007). Finally, the unique
stabilization of receptor conformations can lead to different
patterns of phosphorylation of receptors (‘barcoding’) which
can then dictate patterns of internalization and disposition
after agonism, as in the case of biased ligands that show
different patterns of phosphorylation of μ-opioid receptors
(Just et al., 2013).
In general, there are a number of factors that need to be
considered in the translation of biased activity profiles meas-
ured in vitro and the therapeutic phenotypic activity of the
molecule in vivo. Variation of biased activity stems from the
relative importance of efficacy versus affinity constituting
the bias, the relative intrinsic efficacy of the molecule for the
various signalling systems, the impact of the conformational
bias on receptor phosphorylation, the interaction of the mol-
ecule with organs of varying sensitivity (receptor density) and
the importance of varying cell types in the body. While many
of these effects cannot easily be predicted, the linking of in
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Figure 8
A biased signal from the receptor (top concentration-response
curves) is processed further by the cell. The relative importance, in
terms of stoichiometric reagents and sensitivity, of the two pathways
is determined by the cell type which then modifies the receptor
signal to form an altered emphasis of the signalling. This can alter the
observed bias of the agonist signal.

































Bias plot (regression of responses in one cell line as a function of
responses to the same target in another cell line) for dopamine
receptor-mediated agonist responses producing cell electrical
impedance for receptors transfected into U-2 cells versus SK-N-MC
cells. Numbers in table represent ΔΔLog(τ/KA) values with dopamine
as the reference agonist. These data indicate that A77636 produces
uniquely selective higher levels of response in U-2 cells over SK-N-MC
cells. Data from Peters and Scott (2009).
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indices (ΔΔLog(τ/KA) and ΔLog(αβ) values) will, hopefully,
provide a way forward to allow medicinal chemistry to opti-
mize desired therapeutic profiles.
The effect of functional allostery in
drug discovery
The most important technical advance in the pharmacology
of drug discovery in recent years has been the introduction of
multiple assays of receptor function, that is, new eyes to see
what behavioural changes ligands cause in the receptor
towards its cellular host. These new eyes to see have defined
collateral efficacies in molecules and greatly expanded what
‘efficacies’ may be available for therapeutic exploitation.
Hand in hand with these advances has come the capability to
screen for new molecules in functional, rather than only
binding, assays. Whereas historically, a binding hit in a
screening assay would be quantitatively assessed for affinity
and possible agonism and selectivity, the options have
increased to testing for efficacy in a broad range of assays
(pathway selective agonism, internalization of receptors,
β-arrestin activation) and quantification of ligand bias. In
addition, the introduction of functional screening assays has
increased the likelihood of detecting allosteric ligands (Rees
et al., 2002), adding an imperative to test for orthosteric
versus allosteric mechanism of action of new ligands. If a
ligand is found to act allosterically, then actions on natural
signalling must be assessed with quantification of possible
induction of bias on endogenous effects. Also, if bias is
detected, either in direct agonism or induced allosteric modi-
fication, then a further assessment of the source of that bias
(either through selective efficacy or affinity) would be benefi-
cial to further determine predicted activity in vivo.
While the required testing for lead optimization of screen-
ing hits has expanded with our increased knowledge of recep-
tor function, theoretically so too has our ability to better
define what will be therapeutic efficacy. For the period 2008–
2010, it was reported that 50% of new drug candidate failures
were due to failures in efficacy (Arrowsmith, 2011). In many
cases, it might be supposed that discovery programmes
carried out their mandate and attained their predefined target
molecule only to find that the predicted efficacy was insuffi-
cient to alleviate the pathological condition, that is an incor-
rect efficacy was identified as being relevant to the disease
state. The introduction of allosteric molecules may produce a
finer modification of pharmacological systems. In addition,
the production of bias signals to cells may assist in more
accurate determination of candidate molecule profiles for in
vivo testing, that is focus efficacy to be a sharper chemical
scalpel to modify pathological signalling in disease. Hope-
fully, this will increase the options for testing various drug
efficacies in diseases to identify the correct one or the com-
bination of efficacies needed.
However, such optimism should not be unbridled by
some important caveats relating to the drug discovery
process. Many of the signalling processes targeted by biased
ligands have differential kinetics of actions in cells and ‘snap-
shot’ assays of biased responses may have limited predictive
value if the kinetics of actions are not accounted for. Another
possible caveat relates to the probability of detecting new
molecules with uniquely biased properties with conventional
assays used in the drug industry (which often generate ‘me
too’ ligands). However, the evidence that biased ligands will
not emerge even from these efforts is still not conclusive. This
is because bias is a relatively new phenomenon and there has
not yet been history available to determine if it is a rare drug
property or not. A similar situation was present in discovery
in 1989 when inverse agonism was first reported by Costa and
Herz (1989); the paucity of constitutively active receptor
assays in pharmacology led to a concomitant paucity of
inverse agonism. As constitutively active assay systems
became available, the prevalence of inverse agonism as an
observed drug property dramatically increased (Kenakin,
2004). This could be the case for biased signalling as well. As
molecules are subjected to proper scrutiny, it may be that
biased signalling will be identified. From a theoretical point
of view, the ensemble view of receptor function predicts this
to be the case. Specifically, it would be difficult to imagine
that two ligands would produce identical conformational
ensembles to cells upon binding, which would be the
required condition for two ligands not to be biased with
respect to each other. From this point of view, the appearance
of a biased agonist phenotype would then depend on the
nature of the receptor conformations enriched by the ligand
and the ability of the cell to detect these. Therefore, it is not
known whether bias is a rare or common drug property and
this is still within the realm of speculation until enough
pharmacology around this effect is known.
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Appendix
Quantification of positive allosteric
modulator effects
In terms of the Black/Leff operational model (Black and Leff,
1983), the response to an agonist [A] for a signalling pathway















where τA1 is the efficacy of the agonist for signalling pathway
1 and KA1 is the affinity of the agonist for the receptor when
activating signalling pathway 1. Under these circumstances,
the transduction coefficient (Kenakin et al., 2012) for
agonism is given as:
Log KA Aτ 1 1[ ] (2A)
In the presence of a saturating concentration of a positive
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Where the efficacy of the agonist [A] is βτA1 and the affinity
of agonist [A] for the receptor is αKA1. Therefore, the
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Under these circumstances, the ratio of log transduction coef-
ficients for agonism in the absence and presence of the modu-
lator is given from equations 2A and 4A as:
ΔLog K LogA A modulatorτ α β1 1 1 1( ) = ( ) (5A)
The effects of the agonist on a second signalling pathway
(designated pathway 2) yield analogous equations to equa-
tions 1 to 5. Therefore, the logarithm of the induced bias is
given as the difference of the Log(αβ) values as:
Log induced bias Log Log Log( )[ ] = ( ) − ( ) = ( )α β α β αβ1 1 2 2 Δ (6A)
and
Induced bias Log= ( )10Δ αβ (7A)
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